Sanofi announced a €300 million investment to expand its site in Geel, Belgium. The investment furthers Sanofi’s commitment to driving the future of biologics by expanding manufacturing and commercial capabilities in order to ensure quality, capacity, and scale.
Through the investment, Sanofi plans to adapt and expand existing production capabilities to support Sanofi’s pipeline of monoclonal antibodies. Updates to the existing facility will include the development of new laboratories focused on quality control and manufacturing sciences.
Philippe Luscan, Executive Vice President, Global Industrial Affairs and President of Sanofi in France said, This investment not only strengthens our goal of becoming a leader in biologics but represents our focus on patients’ needs.
We have a robust development pipeline of biological molecules, including monoclonal antibodies, and this investment furthers our work and expertise in key disease areas such as cardiovascular disease, rheumatoid arthritis, and atopic dermatitis. This is an exciting opportunity for our site in Geel and we are very pleased with the support we received from the Government of Flanders, the Flanders Investment and Trade and the Flanders Entrepreneurship agency.”
